<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02767505</url>
  </required_header>
  <id_info>
    <org_study_id>478-15</org_study_id>
    <nct_id>NCT02767505</nct_id>
  </id_info>
  <brief_title>Bypass Equipoise Sleeve Trial (BEST)</brief_title>
  <acronym>BEST</acronym>
  <official_title>Bypass Equipoise Sleeve Trial, Gastric Bypass or Sleeve Gastrectomy: A Randomized Controlled National Multicenter Study (BEST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ersta Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Region Örebro County</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kalmar County Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lindesbergs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danderyd Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Skaraborg Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norrtälje Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sodertalje Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Östra Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mora Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Torsby Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stockholm South General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gävle Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lycksele Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Falu Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vrinnevi Hospital, Norrköping</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Göteborg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is nationwide registry-based randomized clinical multicenter trial in which patients
      will be randomized to gastric bypass (RYGB) or sleeve gastrectomy (SG). The co-primary
      endpoint are weight control over 5 years and the amount of severe adverse events.
      Additionally the investigators have predefined a number of secondary endpoints, and the trial
      has a sufficient number of patients to allow comparisons across subgroups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Follow-up of the patients will use the routines respectively for regular follow-up on the
      Scandinavian Obesity Surgery Registry (SOReg) after 6v, 1 year, 2 years, and after 5 years.

      In order to evaluate if SG has advantages compared to the previous standard, the
      investigators want to examine whether SG operations are equivalent (non-inferiority) for
      weight loss and weight stability five years after surgery in comparison to GBP, and if SG is
      associated with fewer long-term complications (superiority). The primary outcome measure
      emanates from assessment of long term weight management and the frequency of serious
      complications.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight loss</measure>
    <time_frame>5 years</time_frame>
    <description>Non-inferiority for SG is defined as &lt; 5% weight difference</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>5 years</time_frame>
    <description>Superiority for SG is defined as having 35 % less serious adverse events in comparison to GBP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>1 and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight loss</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Between baseline and 1 and 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with arterial cardiovascular events</measure>
    <time_frame>Baseline, 1, 2 and 5 years</time_frame>
    <description>Composite of myocardial infarction+ stroke+ other occlusive arterial condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with venous event</measure>
    <time_frame>Baseline, 1, 2 and 5 years</time_frame>
    <description>Composite of Deep vein thrombosis+ Pulmonary emboli+ other venous event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with diabetes requiring drug treatment</measure>
    <time_frame>Baseline, 1, 2 and 5 years</time_frame>
    <description>Development of diabetes measured as numbers of patients having a diabetes diagnosis and oral medication and injection therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a psychiatric morbidity</measure>
    <time_frame>Baseline, 1, 2 and 5 years</time_frame>
    <description>Number of patients with a psychiatric morbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with hypertension treatment</measure>
    <time_frame>Baseline, 1, 2 and 5 years</time_frame>
    <description>Number of patients with hypertension treatment (any type of Medical treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients diagnosed with a malignancy</measure>
    <time_frame>Baseline, 1, 2 and 5 years</time_frame>
    <description>Number of patients diagnosed with a malignancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with dyslipidemia treatment</measure>
    <time_frame>Baseline, 1, 2 and 5 years</time_frame>
    <description>Number of patients with diagnosis of dyslipidemia and on oral lipid lowering treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight in men and women</measure>
    <time_frame>1, 2 and 5 years</time_frame>
    <description>Analyses of the primary outcome weight in men and women</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serious adverse events in men and women</measure>
    <time_frame>1, 2 and 5 years</time_frame>
    <description>Analyses of the primary outcome serious adverse events in men and women</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight in patients with BMI &gt;43 vs &lt;43 kg/m2.</measure>
    <time_frame>1, 2 and 5 years</time_frame>
    <description>Analyses of the primary outcome weight in patients with BMI &gt;43 vs &lt;43 kg/m2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events in patients with BMI &gt;43 vs &lt;43 kg/m2</measure>
    <time_frame>1, 2 and 5 years</time_frame>
    <description>Analyses of the primary outcome serious adverse events in patients with BMI &gt;43 vs &lt;43 kg/m2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight in patients aged 18-25 y, 25-50 y, or &gt;50 y</measure>
    <time_frame>1, 2 and 5 years</time_frame>
    <description>Analyses of the primary outcome weight in patients aged 18-25 y, 25-50 y, or &gt;50 y</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events in patients aged 18-25 y, 25-50 y, or &gt;50 y</measure>
    <time_frame>1, 2 and 5 years</time_frame>
    <description>Analyses of the primary outcome serious adverse events in patients aged 18-25 y, 25-50 y, or &gt;50 y</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mineral nutritional status</measure>
    <time_frame>2 and 5 years</time_frame>
    <description>Serum concentrations of iron depots, zinc, magnesium, selenium and copper</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin nutritional status</measure>
    <time_frame>2 and 5 years</time_frame>
    <description>Serum concentrations of vitamins (Vitamin B12, Vitamin D, Vitamin A, thiamin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of albumin</measure>
    <time_frame>2 and 5 years</time_frame>
    <description>Serum concentrations of Albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of Life assessed with EQ-5D</measure>
    <time_frame>Baseline, 1, 2 and 5 years</time_frame>
    <description>Assessed with EQ-5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of Life assessed with Obesity Problems (OP)</measure>
    <time_frame>Baseline, 1, 2 and 5 years</time_frame>
    <description>Assessed with Obesity Problems (OP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of Life assessed with SF-36</measure>
    <time_frame>Baseline, 1, 2 and 5 years</time_frame>
    <description>Assessed with SF-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alcohol consumption</measure>
    <time_frame>1, 2 and 5 years</time_frame>
    <description>Assessed by AUDIT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastro-esophageal reflux disease</measure>
    <time_frame>1, 2 and 5 years</time_frame>
    <description>Gastro-esophageal reflux disease is defined as present/ not present in at least one of following modalities: Questionnaire DeMeester score, 24h pH manometry and/or gastroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fracture incidence</measure>
    <time_frame>2 and 5 years</time_frame>
    <description>From clinical data and national registry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone density and body composition</measure>
    <time_frame>2 and 5 years</time_frame>
    <description>DEXA in at least a subgroup of 500+500</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality and cause of death</measure>
    <time_frame>5, 10, 20 and 30 years</time_frame>
    <description>National Cause of Death registry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care consumption, In hospital registry</measure>
    <time_frame>5, 10, 20 and 30 years</time_frame>
    <description>Data from In hospital registry (Days in hospital)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care consumption,</measure>
    <time_frame>5, 10, 20 and 30 years</time_frame>
    <description>Data from Outpatient registry ( number of visits)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care consumption</measure>
    <time_frame>5, 10, 20 and 30 years</time_frame>
    <description>National drug registry (type of drug)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of co-morbidities from national registry data</measure>
    <time_frame>5, 10, 20, 30 years</time_frame>
    <description>National stroke registry, National Cardiac registry, National Diabetes Registry, Cancer registry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Formal cost effective analysis</measure>
    <time_frame>5, 10 and 20 years</time_frame>
    <description>Cost per quality-adjusted life-year and life-year)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary intake and eating patterns</measure>
    <time_frame>1, 2 and 5 years</time_frame>
    <description>Questionnaire regarding food intake (E14x)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary intake and eating patterns</measure>
    <time_frame>1, 2 and 5 years</time_frame>
    <description>Three Factor Eating Questionnaire (TFEQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary intake and eating patterns</measure>
    <time_frame>1, 2 and 5 years</time_frame>
    <description>Food Frequency form</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastro-intestinal side effects</measure>
    <time_frame>1, 2 and 5 years</time_frame>
    <description>Questionnaire: Gastro-intestinal Symptom Rating Score (GSRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dumping symptoms</measure>
    <time_frame>1, 2 and 5 years</time_frame>
    <description>Questionnaire: Dumping Symptom Rating Score (DSRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>30 days postop, 1 year, 2 years and 5 years</time_frame>
    <description>Clinical data combined with national registry data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-operative outcome, Complications</measure>
    <time_frame>Up to 30 days postop</time_frame>
    <description>Complications; Surgical (minor/major) and medical</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-operative outcome, surgical time</measure>
    <time_frame>Up to 30 days postop</time_frame>
    <description>surgical time (min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-operative outcome, sick leave</measure>
    <time_frame>Up to 30 days postop</time_frame>
    <description>sick leave (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-operative outcome, length of stay</measure>
    <time_frame>Up to 30 days postop</time_frame>
    <description>length of stay (days)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Severe Obesity</condition>
  <arm_group>
    <arm_group_label>Sleeve gastrectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laparoscopic sleeve gastrectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gastric bypass</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Laparoscopic Roux-en-Y gastric bypass</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>gastric bypass</intervention_name>
    <description>Type of surgery: gastric bypass</description>
    <arm_group_label>Gastric bypass</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sleeve gastrectomy</intervention_name>
    <description>Typ of surgery: sleeve gastrectomy</description>
    <arm_group_label>Sleeve gastrectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 35-50 kg/m2

          -  Ability to understand and decide on the merits of the study participation

          -  Accepted for bariatric surgery

        Exclusion Criteria:

          -  Previous bariatric surgery, antireflux surgery or other gastric surgery

          -  Moderate to severe reflux disease or known hiatus hernia &gt;4 cm

          -  Planned significant surgery at the same time

          -  Inflammatory bowel disease

          -  ongoing drug or substance abuse

          -  not appropriate to randomize the patient, according to surgeon
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torsten Olbers</last_name>
    <role>Principal Investigator</role>
    <affiliation>Göteborg University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Torsten Olbers, MD, PhD</last_name>
    <phone>+46 31 342 83 47</phone>
    <email>torsten.olbers@gu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Niclas Björnfot, RN</last_name>
    <phone>+46 31 342 84 04</phone>
    <phone_ext>8484</phone_ext>
    <email>niclas.björnfot@vgregion.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torsten Olbers, MD, PhD</last_name>
      <phone>+46 31 342 83 47</phone>
      <phone_ext>8347</phone_ext>
      <email>torsten.olbers@gu.se</email>
    </contact>
    <contact_backup>
      <last_name>Niclas Björnfot, RN</last_name>
      <phone>+46 31 342 84 04</phone>
      <phone_ext>8404</phone_ext>
      <email>niclas.bjornfot@vgregion.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Östra Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>416 50</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per Björklund, MD</last_name>
      <email>per.bjorklund@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kalmar County Hospital</name>
      <address>
        <city>Kalmar</city>
        <zip>392 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Berggren, MD</last_name>
      <email>johan.berggren@ltkalmar.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lindesbergs Hospital</name>
      <address>
        <city>Lindesberg</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Ottosson, MD</last_name>
      <email>johan.ottosson@regionorebrolan.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norrtälje hospital</name>
      <address>
        <city>Norrtälje</city>
        <zip>761 29</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urs Wenger, MD</last_name>
      <email>urs.wenger@tiohundra.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skaraborgs Hospital</name>
      <address>
        <city>Skövde</city>
        <zip>541 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bengt Orrenius, MD</last_name>
      <email>bengt.h.orrenius@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ersta Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>116 91</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Thorell, MD, PhD</last_name>
      <phone>+46 8 714 65 41</phone>
      <phone_ext>6541</phone_ext>
      <email>anders.thorell@erstadiakoni.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Danderyds Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Näslund, MD, PhD</last_name>
      <phone>+46 8 12355017</phone>
      <email>erik.naslund@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Södertälje Hospital</name>
      <address>
        <city>Södertälje</city>
        <zip>152 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per Lundqvist, MD</last_name>
      <email>per.lundquist@sodertaljesjukhus.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingemar Näslund, MD</last_name>
      <email>ingemar.naslund@regionorebrolan.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2015</study_first_submitted>
  <study_first_submitted_qc>May 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2016</study_first_posted>
  <last_update_submitted>July 4, 2017</last_update_submitted>
  <last_update_submitted_qc>July 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

